ProfileGDS5678 / 1421034_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 93% 94% 93% 91% 95% 94% 94% 95% 93% 92% 93% 92% 92% 93% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.8354993
GSM967853U87-EV human glioblastoma xenograft - Control 28.2732794
GSM967854U87-EV human glioblastoma xenograft - Control 38.0201393
GSM967855U87-EV human glioblastoma xenograft - Control 47.5765891
GSM967856U87-EV human glioblastoma xenograft - Control 58.4059995
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.8304794
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.9677194
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.4206595
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.7972593
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.6524692
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.795193
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.6397292
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.6707692
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.8333293